Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab with Nivolumab or Ipilimumab in Advanced Melanoma
NCT03425461Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pepinemab in melanoma (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Maximum tolerated dose at 21 days. Started Jun 2018; status: terminated.
02
Drugs
pepinemab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03425461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425461.